Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT), Government of India has facilitated the establishment of the r-VSV vaccine manufacturing platform for the first time in India by supporting Aurobindo Pharma's COVID-19 vaccine development.
Aurobindo Pharma Limited is developing a vaccine for SARS COV-2 (COVID-19) through its wholly owned US subsidiary Auro Vaccines. The SARS COV-2 vaccine candidate is based on the company's proprietary replication-competent, attenuated, recombinant vesicular stomatitis (VSV, VesiculoVax™) vaccine delivery platform.
Aurobindo is in the process of setting up a state-of-art manufacturing facility for viral vaccines which will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will comply to global standards. The Company's COVID-19 vaccine development is going as per plan.
Commenting on the collaboration with Aurobindo, Dr Renu Swarup, Secretary, DBT and Chairperson, BIRAC said, "The partnership with Aurobindo is to serve the country's need for a vaccine to fight this pandemic. The government is focussed on creating an ecosystem that nurtures and encourages new product innovation to address the most relevant issues to our society."
Commenting on the collaboration, Mr N. Govindarajan, Managing Director, Aurobindo Pharma Limited, said "It is a matter of immense pride that BIRAC has placed its trust on our vaccine capabilities. The senior leadership of Aurobindo and Auro Vaccines has extensive experience in development, production and commercialization of several vaccines."
Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.795.45 as compared to the previous close of Rs. 802.75. The total number of shares traded during the day was 56950 in over 1866 trades.
The stock hit an intraday high of Rs. 815 and intraday low of 791.4. The net turnover during the day was Rs. 45721240.